 HAUPPAUGE, N.Y., July 20, 2021 GLOBE NEWSWIRE -- Chembio Diagnostics, Inc. Nasdaq: CEMI, a leading point-of-care diagnostic company focused on infectious diseases, announced its receipt today of a 28.3 million purchase order from Bio-Manguinhos for the purchase of Chembios DPP SARS-CoV-2 Antigen tests for delivery during 2021 to support the urgent needs of Brazils Ministry of Health in addressing the COVID-19 pandemic. The DPP SARS-CoV-2 Antigen test is designed to detect the SARS-CoV-2 antigen, which indicates an active COVID-19 infection, in only 20 minutes using a minimally invasive nasal swab. Chembios delivery of the full number of tests covered by the purchase order may be affected by limitations of Chembios supply chain, staffing, and liquidity, and other matters outside Chembios control. 